Serious infection risk in people treated with infliximab for severe psoriasis

British Journal of Dermatology 2026 Open access

Read full text
Authors: Heber Rew Bright, Catherine H. Smith, Philip Laws, Nick J. Reynolds, Duc Binh Phan, Mark Lunt, Richard Bruce Warren, Zenas Z N Yiu
DOI: 10.1093/bjd/ljag032
Cited by: 0

Abstract

The risk of serious infection in people with severe psoriasis treated with infliximab was examined in a cohort study using real-world data from BADBIR. The propensity score method and inverse probability of treatment weights were used to balance covariates across treatment groups. An Andersen–Gill recurrent Cox model was used to estimate hazard ratios for comparisons with infliximab. Our findings suggest that infliximab is associated with an increased risk of serious infection vs. adalimumab, secukinumab, ustekinumab and standard treatments.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Spondyloarthritis Studies and Treatments

Publication details

Journal / source
British Journal of Dermatology
Volume
194
Issue
5
Pages
964–966
Publication date
27 January 2026
Language
EN